Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupEBOSY 85 3-Year EBITDA Growth Rate is 5.40% as of Dec. 2025, which is 45% below its 10-year median of 9.85. GuruFocus rates EBOSY with a GF Score™ of 85/100 and a GF Value™ of $47.52. The stock has 4 warning signs investors should review. Among 106 Medical Distribution companies, Ebos Group ranks worse than 50.94% on this metric.
During the past 12 months, Ebos Group's average EBITDA Per Share Growth Rate was -5.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 8.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 9.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ebos Group was 24.30% per year. The lowest was -15.50% per year. And the median was 9.85% per year.
Ebos Group (OTCPK:EBOSY) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ebos Group 3-Year EBITDA Growth Rate Related Terms
EBOSY vs MCK, COR, CAH: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Ebos Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ebos Group's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.40% mean?
Ebos Group (EBOSY) has a 3-Year EBITDA Growth Rate of 5.40% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ebos Group and its competitors. This is 45% below median its historical median of 9.85. According to the industry distribution chart, Ebos Group ranks #54 out of 106 companies in the Medical Distribution industry, placing it in the top 50.9%.
Is Ebos Group's 3-Year EBITDA Growth Rate too high?
Ebos Group's current 3-Year EBITDA Growth Rate of 5.40% is 45% below median its 10-year median of 9.85. The Medical Distribution industry median 3-Year EBITDA Growth Rate is 5.45. Ebos Group's value of 5.40% is 0.9% below this industry median. Based on the distribution chart, Ebos Group ranks #54 out of 106 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ebos Group has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's 3-Year EBITDA Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #54 out of 106 companies for 3-Year EBITDA Growth Rate. This places Ebos Group in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 5.45. Ebos Group's value of 5.40% is 0.9% below this benchmark. While the company's 10-year median is 9.85 vs. the industry median of 5.45, Ebos Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 5.45, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current 3-Year EBITDA Growth Rate of 5.40% is 0.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ebos Group and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 5.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current 3-Year EBITDA Growth Rate is 5.40%, which is 45% below median its own 10-year median of 9.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Ebos Group (EBOSY) has a current 3-Year EBITDA Growth Rate of 5.40%. The stock's GF Value™ is $47.52, compared to a current price of $26.00 — trading 45.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 5.40%, which is 45% below median its 10-year median of 9.85 and 0.9% below the Medical Distribution industry median of 5.45. Ebos Group's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ebos Group (EBOSY), the current 3-Year EBITDA Growth Rate is 5.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (EBOSY) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of $26.00 is trading 45.3% below its estimated GF Value™ of $47.52.
Key valuation signals for EBOSY:
3-Year EBITDA Growth Rate: 5.40% (45% below median its 10-year median of 9.85)
GF Value™: $47.52 vs. price of $26.00 (45.3% below fair value)
Industry Position: 0.9% below the Medical Distribution median (#54 of 106)
No single metric tells the full story. See the EBOSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
85GF Score
Get the complete analysis for EBOSY
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBOSY has been successfully added to your 
